Manipal Health Enterprises Limited Sets Q2 FY27 Results Meeting

Manipal Health Enterprises Limited will consider and announce its Q2 FY27 and H1 FY27 unaudited results on November 13, 2026, with an investor call scheduled from 6:00 pm IST after its Q1 revenue rose 38.1% year-on-year to ₹3,091 crore. The update sets the timing for the company’s next financial disclosure.

When will Manipal Health Enterprises announce Q2 FY27 results?

Manipal Health Enterprises will announce standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, on Friday, November 13, 2026. The company has said its Board of Directors will meet that day to consider and approve the results along with the statutory auditor’s limited review report.

The board meeting had initially been scheduled for November 9, 2026, before being moved to November 13. The notice is an advance intimation of the proposed agenda, rather than a disclosure of the September-quarter financial outcome. Investors will therefore have to wait for the board-approved filing for revenue, profitability, margin, volume and other Q2 metrics.

The company has also scheduled a conference call with investors and analysts on November 13 from 6:00 pm to 7:00 pm IST. The call is intended to discuss financial performance for the second quarter ended September 30, 2026, following the results announcement.

What will the board consider at the November 13 meeting?

The board will consider the standalone and consolidated unaudited financial results of Manipal Health Enterprises for Q2 FY27 and H1 FY27. The agenda also includes the statutory auditor’s limited review report, which accompanies quarterly unaudited financial statements for listed companies.

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015. This regulation requires listed entities to inform exchanges about material events, including board meetings convened to consider financial results.

The company’s trading window for designated persons will remain closed until the end of business on November 15, 2026. Such closures are used to restrict dealing in securities by designated persons while unpublished price-sensitive information relating to financial results is being handled.

What did Manipal Health Enterprises report in Q1 FY27?

Manipal Health Enterprises reported revenue of ₹3,091 crore in Q1 FY27, a 38.1% increase from ₹2,238 crore in the corresponding quarter of FY26. The June-quarter performance provides the most recent reported financial reference point before the September-quarter results are released.

The company said inpatient volumes increased 38.8% year-on-year and outpatient volumes rose 26.0% in Q1 FY27. Network occupancy improved by 290 basis points to 65.0%, indicating higher utilisation as the hospital chain absorbed recently added capacity.

Average revenue per occupied bed, excluding the Sahyadri portfolio, increased 8.7% year-on-year to ₹77,200 per day. The supplied Q1 disclosures also said Sahyadri Hospitals was acquired on October 3, 2025, meaning the prior-year Q1 comparison did not include that portfolio.

Management had identified higher average revenue per occupied bed and operating efficiency as contributors to Sahyadri’s performance. In the wider network, oncology and orthopaedics were cited as drivers of inpatient revenue growth, while the specialty mix within the CONGO-R business rose to 65.4%.

Why are Q2 FY27 results important for hospital-sector investors?

The Q2 FY27 filing will show whether the revenue growth, higher occupancy and volume momentum reported in Q1 FY27 continued through the September quarter. It will also provide the first half-year view of the company’s standalone and consolidated performance after incorporating the operating contribution from its expanded hospital network.

For investors, the relevant measures will include revenue growth, EBITDA, EBITDA margin, profit after tax, occupancy, patient volumes and average revenue per occupied bed. These measures help show the balance between network expansion, capacity utilisation and profitability in a hospital operator’s business model.

The Q1 FY27 data showed that revenue expansion did not automatically translate into a higher reported margin. The company reported an EBITDA margin of 23.8% in Q1 FY27, compared with 26.2% in the year-earlier period, even as revenue rose 38.1%. The September-quarter release will provide the next official update on this margin trend.

No stock-price movement, Q2 financial figure or management outlook has been disclosed in the advance notice. The November 13 result and subsequent analyst call will be the relevant company events for assessing the latest operating and financial position.

How does the Sahyadri acquisition provide context for the results?

Sahyadri Hospitals is an important comparison factor because it was acquired on October 3, 2025, after the Q1 FY26 comparison period. As a result, year-on-year growth in the current financial year includes the effect of a larger hospital network, alongside growth in the legacy business.

In Q1 FY27, Manipal Health Enterprises said the Sahyadri portfolio recorded revenue growth of 12.8% year-on-year and EBITDA growth of 18.7% year-on-year. The company attributed this to higher average revenue per occupied bed and better operating efficiency. The H1 FY27 disclosures will offer a further update on the integration and utilisation of this capacity.

Conclusion

Manipal Health Enterprises has fixed November 13, 2026, for board consideration and announcement of its Q2 and H1 FY27 unaudited results, followed by an investor call the same evening. The scheduled disclosure follows a Q1 FY27 in which revenue reached ₹3,091 crore, supported by higher patient volumes and a 65.0% occupancy rate.

The main next event is the board-approved September-quarter filing and the 6:00 pm IST analyst call on November 13. Investors can watch for updated revenue, margin, occupancy, volume and average-revenue-per-bed data, as well as management commentary on the expanded network and the Sahyadri portfolio.